Core Insights - Elicio Therapeutics has reported promising results from the Phase 2 AMPLIFY-7P trial, indicating that ELI-002 7P can induce antigen spreading in a majority of patients, enhancing immune responses against non-mKRAS neoantigens [1][5] Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, particularly targeting high-prevalence cancers like mKRAS-positive pancreatic and colorectal cancers [6] - The company utilizes its proprietary Amphiphile (AMP) technology to enhance the activation and amplification of cancer-specific T cells, aiming for durable cancer immunosurveillance [6][9] Clinical Trial Results - In the ongoing Phase 2 AMPLIFY-7P trial, 87% (13 out of 15) of evaluated patients exhibited significant T cell responses to non-mKRAS tumor neoantigens, indicating a broadening of the immune response beyond the targeted antigens [3][5] - The median fold change in T cell response over baseline for the Phase 2 trial was reported at 10.6x, demonstrating a robust immune response [3] - The trial included 90 evaluable patients, with 15 selected for antigen spreading analysis based on sufficient blood samples and tumor sequencing data [3] Product Candidate Details - ELI-002 is an off-the-shelf immunotherapy candidate targeting common KRAS mutations, which are implicated in approximately 25% of all solid tumors [6][7] - The ELI-002 7P formulation is designed to provide immune response coverage against seven of the most common KRAS mutations, thereby increasing the potential patient population [8] Future Directions - Elicio plans to expand the application of ELI-002 to other indications, including mKRAS-positive lung cancer and other mKRAS-positive cancers, building on the clinical successes in personalized cancer immunotherapy [6][12]